Skip to main content
SpringerLink
Log in

Pharmacokinetics of high-dose etoposide after short-term infusion

  • Original Articles
  • High-Dose Etoposide, Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of high-dose etoposide (total dose, 2100 mg/m2 divided into three doses given as 30-min infusions on 3 consecutive days) were studied in ten patients receiving high-dose combination chemotherapy followed by autologous bone marrow transplantation. In addition to etoposide, all subjects received 2×60 mg/kg cyclophosphamide and either 6×1,000 mg/m2 cytosine arabinoside (ara-C), 300 mg/m2 carmustine (BCNU), or 1,200 mg/m2 carboplatin. Plasma etoposide concentrations were determined by252Cf plasma desorption mass spectrometry. In all, 27 measurements of kinetics in 10 patients were analyzed. According to graphic analysis, the plasma concentration versus time data for all postinfusion plasma ctoposide values were fitted to a biexponential equation. The mean values for the calculated pharmacokinetic parameters were:t1/2β, 256±38 min; mean residence time (MRT), 346±47 min; AUC, 4,972±629μg min ml−1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6±1.2l/m2; and clearance (CL), 20.4±2.4 ml min−1 m−2. A comparison of these values with standard-dose etoposide pharmacokinetics revealed that the distribution and elimination processes were not influenced by the dose over the range tested (70–700 mg/m2). Also, the coadministration of carboplatin did not lead to significant pharmacokinetic alterations. Although plasma etoposide concentrations at the time of bone marrow reinfusion (generally at 30 h after the last etoposide infusion) ranged between 0.57 and 2.39 μg/ml, all patients exhibited undelayed hematopoietic reconstitution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blume KG, Forman SJ, O'Donell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ (1987) Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015

    Google Scholar 

  2. Burnett AK, Watkins R, Maharaj D (1984) Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission. Lancet 11:1068

    Google Scholar 

  3. Cunningham D, Cummings J, Blackie RB, McTaggart L, Banham SW, Kaye SB, Soukop M (1987) The pharmacokinetics of high dose cyclophosphamide and high dose etoposide. Med Oncol Tumor Pharmacother 5:117

    Google Scholar 

  4. Danigel H, Pflüger KH, Jungclas H, Schmidt L, Dellbrügge J (1985) A combined method of liquid chromatography and mass spectrometry. Cancer Chemother Pharmacol 15:121

    Google Scholar 

  5. Douay L, Gorin NC, Mary IY, Lemarie E, Lopez M, Naiman A, Stachowiak I, Giarratana MC, Baillou C, Salmon F (1986) Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Exp Hematol 14:358

    Google Scholar 

  6. Finn GP, Bozek T, Souhami RL, Slevin ML, Thomas DGT (1985) High-dose etoposide in the treatment of relapsed primary brain tumors. Cancer Treat Rep 69:603

    Google Scholar 

  7. Gouyette A, Deniel A, Pico JL, Droz JP, Baume D, Ostronoff M, Le Bail N, Hayat M (1987) Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. Eur J Cancer Clin Oncol 23:1627

    Google Scholar 

  8. Green JA, Tarpey AW, Warenius HM (1988) Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. Acta Oncol 27:819

    Google Scholar 

  9. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetic of high-dose etoposide (VP16-213) administered to cancer patients. Cancer Res 44:379

    Google Scholar 

  10. Holthuis JJM, Postmus PE, Van Oort PJ, Hulshoff B, Verleun H, Sleijfer DT, Mulder NH (1986) Pharmacokinetics of high dose etoposide (VP16-213). Eur J Cancer Clin Oncol 22:1149

    Google Scholar 

  11. Jungclas H, Pflüger KH, Schmidt L, Hahn M (1989) Quantitative252Cf-PDMS for etoposide. J Phys Coll [C] 50 [Suppl 2]: 41

    Google Scholar 

  12. Köppler H, Pflüger KH, Wolf M, Weide R, Havemann K (1990) High-dose chemotherapy with noncryopreserved autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Hematology and blood transfusion, vol 33. Acute leukemias II. Springer, Berlin Heidelberg New York, p 699

    Google Scholar 

  13. Köppler H, Pflüger KH, Havemann H (1991) High-dose chemotherapy with autologous bone marrow rescue: hematopoietic reconstitution by non-cryopreserved bone marrow. Bone Marrow Transplant 7 [Suppl 2]: 143

    Google Scholar 

  14. Loo JCK, Riegelmann S (1970) Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i. v. infusion. J Pharm Sci 59:53

    Google Scholar 

  15. Meloni G, De Fabritiis P, Carella AM (1990) Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy. Bone Marrow Transplant 5:29

    Google Scholar 

  16. Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol 23:267

    Google Scholar 

  17. Newman EM, Doroshow JH, Forman SJ, Blume KG (1988) Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 43:561

    Google Scholar 

  18. Pflüger KH, Schmidt L, Merkel M, Jungclas H, Havemann K (1987) Drug monitoring of etoposide (VP16-213). Cancer Chemother Pharmacol 20:59

    Google Scholar 

  19. Postmus PE, De Vries EGE, De Vries-Hospers HG, Vriesendorp R, Van Imhoff GW, Holthuis JJM, Smit Sibinga CT, Sleijfer DT, Mulder NH (1984) Cyclophosphamide and VP16-213 with autologous bone marrow transplantation. A dose escalation study. Eur J Cancer Clin Oncol 20:777

    Google Scholar 

  20. Schmitz N, Gassmann W, Rister M, Johannson W, Suttorp M, Brix F, Holthuis JJM, Heit W, Hertenstein B, Schaub J, Löffler H (1988) Fractionated total body irradiation and high-dose VP16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 72:1567

    Google Scholar 

  21. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109

    Google Scholar 

  22. Spinilo JA, Dicke KA, Horwitz LJ (1990) Double intensification with amsacrine/high-dose ara-C and high-dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia. Bone Marrow Transplant 5:111

    Google Scholar 

  23. Spitzer G, Verma DS, Fisher R, Zander A, Vellekoop L, Litam J, McCredie KB, Dicke KA (1980) The myeloid progenitor cell—its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood 55:317

    Google Scholar 

  24. Van Hoogenhuijze J, Lankelma J, Stam J, Pinedo HM (1987) Unchanged pharmacokinetics of VP16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide. Eur J Cancer Clin Oncol 23:807

    Google Scholar 

  25. Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA (1983) High-dose VP16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1:701

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kernchemie, Fachbereich Physikalische Chemie, Philipps-Universität Marburg, W-3550, Marburg, Federal Republic of Germany

    P. Köhl & L. Schmidt

  2. Klinische Nuklearmedizin, Fachbereich Humanmedizin, Philipps-Universität Marburg, W-3550, Marburg, Federal Republic of Germany

    P. Köhl, H. W. Fritsch & H. Jungclas

  3. Zentrum für Innere Medizin, Abt. Hämatologie/Onkologie, Fachbereich Humanmedizin, Philipps-Universität Marburg, Baldingerstrasse, W-3550, Marburg, Federal Republic of Germany

    H. Köppler, J. Holz & K. H. Pflüger

Authors
  1. P. Köhl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Köppler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. W. Fritsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Holz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. H. Pflüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Jungclas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köhl, P., Köppler, H., Schmidt, L. et al. Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother. Pharmacol. 29, 316–320 (1992). https://doi.org/10.1007/BF00685951

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685951

Keywords

Search

Navigation